Device Trial Radar · NCT06525571
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 20, 2024
Primary completion
Jan 4, 2027
Study completion Jan 4, 2028
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Photocure ASA
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.
Conditions
- Bladder Cancer
Interventions
CysviewDrug
Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.
Karl Storz D-Light C Photodynamic Diagnostic (PDD) systemDevice
Cystoscopy procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Residual disease burdenTime frame: Up to 24 months
- Minimal residual disease burdenTime frame: Up to 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Johns Hopkins University School of Medicine
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.